NuvOx Therapeutics, Inc.
NUOXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
Get an email about NUOX's next catalysts
Track NuvOx Therapeutics (NUOX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 0 past
NanO2TM Phase 2 Est. Readout (RESTORE)
Estimated primary completion for NanO2TM trial (NCT03862430) in Glioblastoma Multiforme. Topline data typically follows completion by weeks to months.
Source| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NanO2TM | Phase 2 | Glioblastoma Multiforme | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NuvOx Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in NuvOx Therapeutics, Inc.'s (NUOX) pipeline across Phase 2. Its lead program is NanO2TM (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NuvOx Therapeutics, Inc.'s next FDA catalyst?→
NuvOx Therapeutics, Inc.'s (NUOX) next tracked catalyst is a Phase 2 readout expected June 30, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NUOX biotech catalysts?→
Add NUOX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NuvOx Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.